Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Chimerix (CMRX) Tops Q1 EPS by 9c; Interim Topline Advise Data Provided, AdV Level Reduction Noted
May 9, 2016 7:33 AM EDTChimerix (NASDAQ: CMRX) reported Q1 EPS of ($0.57), $0.09 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $2.79 million.
Today, Chimerix provided topline results from an interim analysis of week 24 data from AdVise which shows a strong antiviral effect which was correlated with overall survival. The company is working closely with medical advisors to plan a prospective, comparative trial in patients with serious adenovirus (AdV) infection.
In August 2015, the Company completed enrollment of the AdVise trial of brincidofovir (BCV) as a... More
